Microbiome startup sells off assets; Faron's PhI/II data in bone marrow cancer; AM Pharma touts biomarker results

11 Oct 2023

AcquisitionImmunotherapyMicrobial therapy

Microbiome startup sells assets, goes dark: Federation Bio sold some of its assets and erased its website three years since emerging with $50 million . Kanvas Biosciences, another microbiome startup, said Wednesday that it bought two of Federation’s investigational therapeutics, a microbial library and other IP. It also gained access to a cell banking operation in South San Francisco and poached Federation’s science chief Lee Swem, naming him chief development officer. Venrock, Horizons Ventures and other firms had bankrolled Federation’s plans to take gut bacteria and poop to make therapies for inflammatory bowel disease, a rare metabolic disorder known as enteric hyperoxaluria and cancer patients who don’t benefit from certain immunotherapies. — Kyle LaHucik

For more details,please visit the original website

The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.

Organizations

Microbiome

AM-Pharma BV

Microbiome Insights, Inc.

[+2]

Indications

Bone Marrow NeoplasmsInflammatory Bowel DiseasesMetabolic Diseases

[+2]

Targets

Drugs

Chat with Hiro

Hot reports

GPRC5D Target Patent Research Report

Patsnap Synapse

Global Drug R&D Express (July 2024)

PatSnap Synapse

siRNA Drug Amvuttra Patent Research and Practical Operation Guide

Patsnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.